Vitaprost two-stage therapy significantly cut chronic prostatitis symptoms and improved prostate morphology.
Background
Chronic prostatitis (CP) and lower urinary tract symptoms (LUTS) represent a significant medical challenge, often leading to impaired quality of life. Despite numerous therapeutic approaches, an optimal treatment regimen remains elusive, with many patients experiencing refractory symptoms after initial therapies. The increasing concern over antimicrobial resistance among uropathogens also highlights the need for effective non-antibiotic interventions. This study addresses the gap by evaluating a two-stage Vitaprost regimen for patients who have failed prior treatments, focusing on its clinical efficiency and safety.
Study Design
A prospective non-interventional real-world study, LEVITATE, included 30 men (mean age 36.1+/-4.6 years) diagnosed with CP and LUTS after ineffective previous therapy. Patients received Vitaprost suppositories for 30 days, followed by a switch to Vitaprost tablets for an additional 30 days. Patients were followed for a total of 90 days. Assessments were conducted at four visits using the NIH-CPSI, IPSS, and SF-36 questionnaires, alongside transrectal ultrasound and uroflowmetry. Statistical analysis relied on the Friedman test.
Results
Two-stage Vitaprost therapy demonstrated significant improvements across multiple parameters. The total NIH-CPSI score, a primary measure of prostatitis symptoms, decreased substantially:
The total
NIH-CPSIscore dropped from 12.8+/-1.3 to 8.6+/-0.9, representing a significant reduction of 4.2 points (p<0.0001).
Morphological improvements in the prostate were also notable, with transrectal ultrasound revealing a decrease in fibrotic changes from 46.7% to 16.7% in most patients. Prostate size was also significantly reduced, decreasing from 26.1+/-8.4 mm to 24.1+/-6.8 mm (a 2.0 mm reduction; p<0.0001). Furthermore, patients experienced improvements in voiding parameters and overall quality of life. Crucially, the study reported no adverse events, indicating a favorable safety profile and high adherence to the treatment regimen.
Key Findings
- Total
NIH-CPSIscore decreased by 4.2 points (from 12.8+/-1.3 to 8.6+/-0.9; p<0.0001). - Proportion of prostate fibrotic changes decreased from 46.7% to 16.7%.
- Prostate size decreased by 2.0 mm (from 26.1+/-8.4 mm to 24.1+/-6.8 mm; p<0.0001).
- Improvements in voiding parameters and quality of life were observed.
- No adverse events were recorded, indicating a favorable safety profile.
Why It Matters
Vitaprost two-stage therapy offers a promising non-antibiotic option for chronic prostatitis patients refractory to conventional treatments. This protocol, involving an initial course of suppositories followed by tablets, provides a structured approach that could be integrated into clinical practice. Given the growing concerns about antimicrobial resistance, an effective non-antibiotic intervention like Vitaprost is particularly valuable for managing CP and LUTS. The observed improvements in both symptomatic and morphological parameters suggest a comprehensive therapeutic effect, potentially reducing the burden of chronic symptoms and improving patient quality of life. This study provides real-world evidence supporting its use, offering a potential new strategy for clinicians and patients struggling with persistent prostatitis.
vitaprost
chronic-prostatitis
luts
prostate-health
urogenital
case-series